WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318401
CAS#: 6452-71-7
Description: Oxprenolol is a non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris, abnormal heart rhythms, and high blood pressure.
Hodoodo Cat#: H318401
Name: Oxprenolol
CAS#: 6452-71-7
Chemical Formula: C15H23NO3
Exact Mass: 265.17
Molecular Weight: 265.348
Elemental Analysis: C, 67.90; H, 8.74; N, 5.28; O, 18.09
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Oxprenolol, Coretal, Tevacor, Trasicor
IUPAC/Chemical Name: 1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol
InChi Key: CEMAWMOMDPGJMB-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3
SMILES Code: OC(COC1=CC=CC=C1OCC=C)CNC(C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 265.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Azizi K, Koli MG. Molecular dynamics simulations of Oxprenolol and Propranolol in a DPPC lipid bilayer. J Mol Graph Model. 2016 Mar;64:153-64. doi: 10.1016/j.jmgm.2016.01.009. Epub 2016 Jan 28. PubMed PMID: 26851866.
2: Först G, Cwiklik L, Jurkiewicz P, Schubert R, Hof M. Interactions of beta-blockers with model lipid membranes: molecular view of the interaction of acebutolol, oxprenolol, and propranolol with phosphatidylcholine vesicles by time-dependent fluorescence shift and molecular dynamics simulations. Eur J Pharm Biopharm. 2014 Aug;87(3):559-69. doi: 10.1016/j.ejpb.2014.03.013. Epub 2014 Mar 28. PubMed PMID: 24681296.
3: Bradamante V, Krnić Z, Zrinski R, Konjevoda P, Reiner Z. Changes in butyrylcholinesterase activity and serum lipids after oxprenolol and glibenclamide treatments in non-diabetic rats. Arzneimittelforschung. 2006;56(2):64-9. PubMed PMID: 16572919.
4: Görlitzer K, Lorenz A. [Medium sized rings from alprenolol and oxprenolol]. Pharmazie. 2004 Oct;59(10):763-9. German. PubMed PMID: 15544054.
5: Braza AJ, Modamio P, Mariño EL. Determination of celiprolol and oxprenolol in human plasma by high-performance liquid chromatography and the analytical error function. J Chromatogr B Biomed Sci Appl. 1998 Nov 6;718(2):267-72. PubMed PMID: 9840437.
6: Jordan CG. How an increase in the carbon chain length of the ester moiety affects the stability of a homologous series of oxprenolol esters in the presence of biological enzymes. J Pharm Sci. 1998 Jul;87(7):880-5. PubMed PMID: 9649358.
7: Leucuta SE, Ponchel G, Duchêne D. Dynamic swelling behaviour of gelatin/poly(acrylic acid) bioadhesive microspheres loaded with oxprenolol. J Microencapsul. 1997 Jul-Aug;14(4):501-10. PubMed PMID: 9229349.
8: Ceccato A, Toussaint B, Chiap P, Hubert P, Crommen J. Enantioselective determination of oxprenolol in human plasma using dialysis coupled on-line to reversed-phase chiral liquid chromatography. J Pharm Biomed Anal. 1997 Jun;15(9-10):1365-74. PubMed PMID: 9226565.
9: Li F, Cooper SF, Mikkelsen SR. Enantioselective determination of oxprenolol and its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. J Chromatogr B Biomed Appl. 1995 Dec 15;674(2):277-85. PubMed PMID: 8788157.
10: Vila E, Badia A. Chronic administration of oxprenolol and metoprolol attenuate sympathetic cardiovascular responses only in non-adrenalectomized pithed rats. J Auton Pharmacol. 1995 Oct;15(5):393-402. PubMed PMID: 8744979.
11: Laethem ME, Rosseel MT, Wijnant P, Belpaire FM. Chiral high-performance liquid chromatographic determination of oxprenolol in plasma. J Chromatogr. 1993 Nov 24;621(2):225-9. PubMed PMID: 8294544.
12: Gupta PK, Lim JK, Zoest AR, Lam FC, Hung CT. Relative bioavailability of oral sustained-release and regular-release oxprenolol tablets at steady-state. Biopharm Drug Dispos. 1991 Oct;12(7):493-503. PubMed PMID: 1932612.
13: Gluth WP, Sörgel F. Determination of oxprenolol and its glucuronide metabolite in plasma and urine using high-performance liquid chromatography. Pharmazie. 1991 May;46(5):336-9. PubMed PMID: 1896479.
14: Rebandel P, Rudzki E. Dermatitis caused by epichlorohydrin, oxprenolol hydrochloride and propranolol hydrochloride. Contact Dermatitis. 1990 Sep;23(3):199. PubMed PMID: 2149329.
15: Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther. 1990 Aug;4(4):1145-9. PubMed PMID: 1982059.
16: Novákné Pékli M. [Bromatometric determination of oxprenolol]. Acta Pharm Hung. 1990 Jul;60(4):162-4. Hungarian. PubMed PMID: 2239344.
17: O'Mahony D, O'Leary P, Molloy MG. Severe oxprenolol poisoning: the importance of glucagon infusion. Hum Exp Toxicol. 1990 Mar;9(2):101-3. PubMed PMID: 2340193.
18: Obel AO. Effects of chlorthalidone, oxprenolol, and their combination in hypertensive blacks: a randomized double-blind crossover study. J Cardiovasc Pharmacol. 1989 Mar;13(3):465-70. PubMed PMID: 2471894.
19: Davis SS, Washington N, Parr GD, Short AH, John VA, Lloyd P, Walker SM. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy. Br J Clin Pharmacol. 1988 Oct;26(4):435-43. PubMed PMID: 3056482; PubMed Central PMCID: PMC1386566.
20: Fraeyman NF, Dello CD, Belpaire FM. Alpha 1-acid glycoprotein concentration and molecular heterogeneity: relationship to oxprenolol binding in serum from healthy volunteers and patients with lung carcinoma or cirrhosis. Br J Clin Pharmacol. 1988 Jun;25(6):733-40. PubMed PMID: 3203044; PubMed Central PMCID: PMC1386451.
